Redomex

Selected form

Amitriptyline

Method of action: Antidepressant, Antidisuric, Anxiolytic, Psychoanaleptics, Sedative, Timoleptic

Treatment option: Pain, Headache, Depression, Clinical Depression, Migraine, Enuresis, Neuropathic Pain, Bed-Wetting, Spina Bifida

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Redomex

Property	Description
Active ingredient	Amitriptyline (as Amitriptyline hydrochloride)
Form	Oral tablet (film-coated)
Pharmacological class	Tricyclic Antidepressant (TCA)
Common use	Modulating mood and nerve signaling
Origin	Synthetic compound

What Type of Medicine is Redomex?

Redomex is the trade name for a specific medication whose active substance is Amitriptyline, a synthetic psychoactive drug classified as a Tricyclic Antidepressant (TCA). This medication is clinically recognized as a first-generation antidepressant and belongs to the broader group of Central Nervous System (CNS) agents. The classification as a TCA confirms its established role in therapy. Unlike many newer compounds, the chemical structure of Amitriptyline, derived from the dihydrodibenzocycloheptadiene structure, is known for its wide-ranging impact on the central nervous system.

Composition and Pharmaceutical Form

The core chemical entity in Redomex is Amitriptyline, typically incorporated as the salt Amitriptyline hydrochloride. Redomex is delivered as a single-ingredient product, containing only Amitriptyline, formulated into an oral tablet for oral administration. The medication is commonly manufactured as a small, film-coated tablet to ensure stability and mask the taste of the active substance. This synthetic compound is not derived from natural sources but is the result of precise molecular design and established pharmaceutical synthesis.

General Purpose and Mechanism Focus

The general purpose of Redomex is to modulate mood and stabilize emotional balance through its fundamental action on neurochemistry. The drug’s key physiological action is to act as a potent reuptake inhibitor, effectively blocking the absorption of the neurotransmitters serotonin and norepinephrine back into nerve cells. This mechanism increases the concentration of these essential messengers at the synaptic sites. This increased availability of key neurotransmitters is the established process by which the medication helps stabilize nerve signaling pathways, a function that has been widely documented in clinical guidelines globally.

What side effects are possible with Redomex?

Possible Side Effects and Safety Information

The safety profile of Redomex (Amitriptyline), a Tricyclic Antidepressant (TCA), is documented by government regulatory agencies and involves adverse reactions categorized by frequency and the physiological system affected. This information reflects the official understanding of potential risks, ensuring it is strictly descriptive and non-advisory.

Officially Documented Adverse Reactions

Adverse effects are formally classified based on their rate of occurrence in clinical use:

Very Common (Affecting ge 1 in 10): The most frequently documented effects include sedation, somnolence (drowsiness), tremor, and classic anticholinergic effects such as dry mouth and constipation. Increased body weight is also classified as Very Common.
Common (Affecting ge 1 in 100): Reactions include orthostatic hypotension (dizziness upon standing), tachycardia (fast heart rate), headache, and various micturition (urination) disorders.
Rare: Less frequent but documented events include bone marrow depression, cholestatic jaundice, and elevated intraocular pressure.

Special Safety Considerations

The official label highlights specific considerations regarding treatment time and patient populations:

Serious Adverse Reactions: Documented clinically significant risks include cardiac arrhythmias, myocardial infarction (heart attack), and the potential for the emergence of suicidal ideation and behavior, particularly at the start of treatment in younger adults.
Timing Pattern: Many adverse reactions, notably sedation and anticholinergic effects, are often more frequently observed at the beginning of treatment and may lessen with continued use.
Population Notes: Caution is explicitly advised for older adults due to increased susceptibility to effects like orthostatic hypotension. The medication is generally contraindicated or requires dose reduction in individuals with severe hepatic impairment.
Restrictions: An absolute restriction is placed on concurrent use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of Serotonin Syndrome.

Overdose and Emergency Response

Redomex (Amitriptyline) overdose is officially documented in regulatory sources as a serious medical emergency with the potential for severe, life-threatening toxicity. Immediate medical attention is required upon any suspicion of overdose; patients must contact emergency services or poison control and should be transported to a hospital for mandatory observation and care.

Documented manifestations primarily affect the central nervous system (CNS) and the cardiovascular system. CNS effects may progress rapidly from confusion, agitation, and seizures to deep unconsciousness or coma. Cardiovascular toxicity is a critical risk, including the development of severe cardiac arrhythmias, irregular or rapid heartbeat, and severe hypotension, potentially leading to fatal outcomes like cardiac arrest. Other documented signs may include anticholinergic effects such as dilated pupils, dry mouth, and urinary retention.

The official labeling notes that children are especially vulnerable to severe consequences of overdose. The treatment approach described is symptomatic and supportive, as no specific antidote is known. Procedures often involve continuous ECG monitoring for several days and may include the use of activated charcoal for gastrointestinal decontamination or intravenous sodium bicarbonate to manage cardiotoxicity like QRS widening. Hospital monitoring for a minimum of 12-24 hours is typically required for evaluation.

Therapeutic Uses of Redomex

What Redomex Treats: Main Uses and Benefits

Redomex, containing Amitriptyline, is relevant across distinct clinical domains and may be part of symptomatic management to help ease the overall symptom load for patients. The medication is commonly used for its therapeutic role in both psychiatric and non-psychiatric conditions, including the management of Major Depressive Disorder (MDD), chronic neuropathic pain syndromes, and prophylaxis for recurrent headaches (migraine and chronic tension-type headache).

The primary therapeutic focus is on addressing symptoms that may become intense or disruptive, such as pervasive sadness, profound low mood, burning or shooting nerve pain, and the frequent recurrence of headache episodes. The treatment may assist with managing symptoms related to mood instability and supports general well-being during symptomatic phases.

Applied in clinical settings marked by heightened patient distress, Redomex is relevant for managing symptoms that interfere with daily comfort. The medication supports general well-being during symptomatic phases, particularly when symptoms become more disruptive during flare-ups. For conditions characterized by episodic or fluctuating symptom patterns, the use of this medication may assist with managing symptoms related to heightened physiological activity, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Management of Chronic Pain Symptoms

Redomex is commonly used to help manage the symptoms of long-standing nerve pain, assisting patients in coping more steadily with persistent discomfort and assists with maintaining functional stability.

Regulatory References

NIH StatPearls overview

Eligibility and Restrictions for Use

The eligibility for using Redomex (Amitriptyline) is formally restricted by regulatory authorities based on a patient’s age and certain pre-existing conditions. These rules define who is absolutely prohibited from using the medicine (contraindicated) and who requires special caution.

Contraindicated Populations

Redomex must not be used by patients who exhibit known hypersensitivity to the drug, are in the acute recovery phase following a myocardial infarction (MI), or are concurrently taking a Monoamine Oxidase Inhibitor (MAOI), or have stopped an MAOI within the last 14 days. Use is also contraindicated in patients with severe liver disease and in children under 6 years of age.

Age-Specific Eligibility

The medicine is generally approved for adults. For pediatric patients, use is limited; it is approved only for the treatment of nocturnal enuresis in children aged 6 years and older. Safety and efficacy for Major Depressive Disorder in children under 12 are often considered not established. Treatment for older adults (65+) requires cautious initiation, typically using a lower starting dose.

Conditional Use

Use is conditional and requires close supervision in patients with cardiovascular disorders, a history of seizures, or conditions that can be aggravated by the drug’s effects, such as urinary retention or angle-closure glaucoma. For pregnancy and lactation, regulatory guidance advises a careful assessment to ensure the potential benefit to the mother outweighs the potential risk to the fetus or infant.

What should I know about interactions with other medicines?

Redomex Interactions with Other Medicines and Products

Official regulatory information identifies several categories of substances that interact with Redomex (amitriptyline), establishing strict constraints for use.

Interaction Type	Examples of Interacting Substances/Classes
Contraindicated Combinations	Monoamine Oxidase Inhibitors (MAOIs), Cisapride
Serotonergic/PD Risk	Other serotonergic agents (e.g., SSRIs), St. John's Wort
PK/Metabolic Interference	CYP2D6 and CYP2C19 Inhibitors (e.g., Cimetidine, Topiramate)
Additive Effects	Alcohol, Barbiturates, Anticholinergic drugs, CNS Depressants

Co-administration with MAOIs is strictly contraindicated due to the potential for severe reactions, including hyperpyretic crises. A mandatory 14-day separation period is required when switching between Redomex and an MAOI. The combination with other serotonergic medicines and herbal products, such as St. John's Wort, may carry the risk of Serotonin Syndrome.

Simultaneous use with other CNS depressants, including alcohol, may cause additive depressant effects. Furthermore, Redomex is metabolized by hepatic enzymes; co-administration with certain enzyme inhibitors may lead to increased plasma concentrations of Redomex, requiring professional caution. Additionally, Redomex may block the antihypertensive action of certain medications like guanethidine. Due to the risk of arrhythmias, co-administration with other drugs that prolong the QT interval is restricted.

Mechanism of Action

How Redomex Works

The mechanism of Redomex (Amitriptyline) is multi-modal and pleiotropic, engaging multiple signaling systems to influence nerve activity and excitability.

Modulation of Monoamine Signaling via Dual Inhibition

Redomex acts as a reuptake inhibitor by blocking the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET). This action prevents the reabsorption of serotonin ( 5-HT) and norepinephrine ( NE), leading to a sustained increase in their concentration within the synaptic cleft. This inhibition alters signaling dynamics within central nervous system ( CNS) circuits and facilitates the descending inhibitory pathway.

Direct Stabilization of Neuronal Excitability

The drug engages a secondary, non-monoaminergic mechanism by acting as a direct blocker of Voltage-gated Sodium ( Na^+) Channels on nerve cell membranes. This mechanism stabilizes the electrical potential of the neuron, suppressing the flow of ions necessary to propagate spontaneous nerve signals. The resulting physiological effect is a stabilization of the neuronal membrane, which suppresses the transmission of excessive or ectopic nerve signals.

Central Receptor Modulation and Suppression

Redomex exhibits high affinity for several other targets, most notably acting as an antagonist at Histamine H1 and Muscarinic Acetylcholine receptors. The blockade of H1 receptors in the CNS reduces histaminergic activity, resulting in CNS suppression and altering sleep architecture. Similarly, muscarinic antagonism alters autonomic signaling, influencing parasympathetic tone.

Dosage and Administration Information

How to Use Redomex

This section outlines the general principles for the administration and dosing of Redomex (Amitriptyline) based on standard clinical protocols.

Administration and Dosing Protocol

The approved route of administration for the Redomex tablet is oral. The tablets should be swallowed whole with water and can generally be taken either with or without food. The single daily dose, or the largest portion of a divided dose, is often administered at bedtime due to the medication’s known properties.

Administration follows a start-low, titrate-slowly pattern. Treatment typically begins at a low daily amount, such as 10 mg or 25 mg, and is gradually increased in small increments, often 25 mg, over intervals of several days, based on the specific clinical context. For Major Depressive Disorder, the standard adult outpatient dose typically ranges from 50 mg to 100 mg daily, with a maximum generally limited to 150 mg/day. Lower initial doses, such as 10 mg to 25 mg daily, are the standard starting point for older adults.

Course Duration and Withdrawal

Treatment must be continued for a sufficient maintenance period; for instance, at least three months is often utilized to reduce the likelihood of relapse. The dose should be the lowest effective amount that sustains the desired effect. When treatment is to be concluded, the medication must be gradually withdrawn by reducing the dose over a period of several weeks. Abrupt cessation is not part of standard procedural guidelines. For its use in nocturnal enuresis in children, the maximum treatment duration for a single course is limited to three months.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Redomex

The research base for Redomex, which contains the active substance Amitriptyline, is substantial, reflecting its long use in clinical settings. Studies conducted follow strict scientific standards, including comparisons against inactive treatments (placebo) and other established medications. The evidence described here focuses only on the structure of this research base and what findings were reported in the observed populations, without offering clinical guidance.

Evidence for Use in Major Depressive Disorder (MDD)

Research consists of a large number of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Trials primarily evaluated how frequently specific levels of symptom change (response) or resolution (remission) were reported in adults with moderate-to-severe depression. The historical evidence base describes patterns of symptom change observed when compared against an inactive treatment (placebo). However, long-term outcomes regarding symptom patterns and functional status are not well characterized by large-scale, extended-duration controlled trials.

Evidence for Use in Chronic Neuropathic Pain Syndromes

The evidence includes RCTs and specialized Meta-analyses. Outcomes measured focused on patient-reported changes in pain intensity and the impact on sleep quality in adults diagnosed with specific long-standing nerve pain conditions. Findings describe patterns related to changes in reported pain scores observed in studies when compared to inactive treatment over a typical duration of 4 to 12 weeks. A high degree of methodological inconsistency is documented across the various studies, and small sample sizes limit the certainty of some findings.

Areas of Uncertainty and Research Gaps

The majority of existing research on Redomex was evaluated in the general adult population, and data for special populations like the elderly often remain insufficient. Follow-up durations were limited for almost all indications, meaning there is restricted information for long-term outcomes or the persistence of observed effects. Overall, the available evidence highlights what is known—and what is still uncertain—about this medication.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Redomex (FAQ)

Q: What is the general timeline for Redomex to start working for a mood disorder?

Official information indicates that the full therapeutic effect on mood disorders may take several weeks to be observed. Clinical response patterns suggest that patients often experience gradual changes, and patients are generally advised to continue the medication for the duration prescribed by their healthcare provider.

Q: Can Redomex cause heart palpitations or changes in heart rhythm?

Yes, official safety information documents potential effects on the heart. Reported adverse reactions include tachycardia (a fast heart rate) and cardiac arrhythmias (irregular heart rhythms). Any concerns about heart changes should be discussed with a healthcare professional.

Q: How does Redomex affect sleep patterns, and is it best taken in the morning or at night?

Due to its known sedative properties, regulatory guidelines often suggest that the largest single dose, or the entire daily amount, should be taken at bedtime. This practice aims to reduce the impact of drowsiness during daytime hours.

Q: What should be monitored by a doctor while a person is taking Redomex?

If a patient is on prolonged Redomex therapy, their doctor may require periodic monitoring. Official sources indicate that this monitoring can include checks of liver function tests and blood counts. These tests help the prescriber monitor the patient's response and health.

Q: Is Redomex a medication that must be taken consistently every day?

Yes, Redomex is designed for continuous use during the treatment period as prescribed by a healthcare provider. The drug is typically administered as a single daily dose to maintain a consistent level in the body.

Q: How does Redomex potentially help with nerve-related (neuropathic) pain?

The mechanism of action involves inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine in the nervous system. This action is thought to contribute to its observed effect in modulating nerve signals associated with pain.

Q: Does Redomex interact with thyroid medication?

Official drug interaction information notes that taking Redomex concurrently with thyroid hormones may increase the risk of developing a cardiac arrhythmia (irregular heartbeat). Any co-administration should be discussed and monitored by a healthcare professional.

Q: Is Redomex similar to SSRIs like fluoxetine or sertraline, and how do they differ?

Redomex is classified as a Tricyclic Antidepressant (TCA), a first-generation medication. Unlike SSRIs (Selective Serotonin Reuptake Inhibitors), Redomex blocks the reuptake of both serotonin and norepinephrine, which results in pharmacological properties that differ from single-agent classes like SSRIs.

Q: Is it normal to have vivid or unusual dreams after starting Redomex?

Yes, regulatory adverse reaction lists include changes in sleep experience. Some people have reported experiencing vivid dreams or nightmares while taking Redomex.

Q: Can Redomex affect driving or operating machinery?

Official warnings state that Redomex may impair the mental and physical abilities necessary for performing hazardous tasks. Patients should be fully aware of the potential for impairment before deciding to drive or operate machinery.

Q: What is the general consensus on using Redomex during pregnancy or while breastfeeding?

Official guidance states that use during pregnancy requires a careful assessment to ensure the potential benefit to the patient outweighs the potential risk to the fetus. Furthermore, the active substance has been detected in breast milk.

Q: Does Redomex have an effect on sex drive or function?

Yes, official adverse effect documentation reports that changes in sex drive (libido) can occur. Other reported sexual side effects include issues with sexual performance, such as erectile dysfunction.

Q: Do withdrawal symptoms occur when stopping Redomex, and how can they be minimized?

Yes, abrupt cessation of Redomex may lead to withdrawal symptoms like nausea, headache, and a general feeling of malaise. Regulatory guidelines recommend that discontinuation must be managed by a healthcare provider, typically by a gradual reduction of the dose over time.

Q: Are there any dietary restrictions or food interactions associated with Redomex?

Regulatory information states that Redomex tablets can generally be taken with or without food. There are no specific dietary restrictions mentioned for typical use, although interactions with other drugs and alcohol are noted.

Q: Can Redomex cause temporary confusion or memory issues, especially in the elderly?

Yes, official reports list confusion as a possible side effect. The elderly population is noted as being particularly susceptible to these types of central nervous system effects from the medication.

Q: What should I know about the 'black box' warning on this type of medication?

Redomex, like other similar medications, carries an official Boxed Warning from the FDA. This warning highlights an increased risk of suicidal thinking and behavior that may occur in children, adolescents, and young adults (up to age 24) when treatment is started or the dose is adjusted.

How should Redomex be stored and disposed of?

Redomex (amitriptyline hydrochloride tablets) must be stored at Controlled Room Temperature between 20 C to 25 C (68 F to 77 F), with allowed temporary excursions from 15 C to 30 C (59 F to 86 F). The medicine must be kept in a tight, light-resistant container, stored in a dry place, and kept from freezing to preserve product stability. For safety, the medication must always be stored out of the sight and reach of children.

Disposal of any unused or expired Redomex must follow local regulations. Due to environmental concerns documented in regulatory safety data, the product should not be released into the environment, meaning disposal must avoid sewers, drains, and natural waterways. Approved drug take-back programs are the recommended method for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Belgium

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z